Immunotherapies Shine at ASCO Annual Meeting
FDA-approved immunotherapies are showing efficacy in different cancer types and combination therapies with new biologics are displaying increased efficacy.
Diagnosis & Disease Information
For Breast Cancer, Docetaxel Improves Progression-Free Survival
Docetaxel/capecitabine regimen for breast cancer followed by capecitabine maintenance led to longer progression-free survival.
Certain Taxane Schedules May Improve Outcomes in Breast Cancer
Weekly paclitaxel and every-3-week docetaxel regimens improved clinical outcomes in women with breast cancer.
Adding Everolimus May Improve Progression-Free Survival in Advanced Breast Cancer
Addition of everolimus notably prolonged progression-free survival in the HR-negative, HER2-positive breast cancer population.
Similar Patient-Reported Outcomes with Exemestane, Tamoxifen in Breast Cancer
No strong indication to favor either exemestane or tamoxifen for treatment of premenopausal women with early breast cancer.
Prenatal DDT Exposure Linked with Higher Breast Cancer Risk
Women exposed to the chemical in utero may be more likely to develop breast cancer.
Higher Breast Cancer Risk in Obese, Postmenopausal Women
Risk for breast cancer among obese women may be up to 58 percent higher than for normal-weight postmenopausal women.
Once-Weekly Paclitaxel Remains Preferred for Advanced Breast Cancer
Paclitaxel once per week remains the preferred palliative chemotherapy in patients with chemotherapy-naive advanced breast cancer.
Study Detects Novel Genetic Markers of Breast Cancer Survival
Researchers have detected two new genetic markers of breast cancer survival.
Worse Outcomes in Patients Managed Without Radiotherapy After Chemo for Breast Cancer
Patients managed without radiotherapy after neoadjuvant chemotherapy for breast cancer have a significantly worse outcome.
- Loading...
Loading...
Next post in ASCO 2015
Loading... 
Loading...